Selling Stockholder Registers 2 Million Shares for Resale Amidst Nasdaq Delisting Threat and Going Concern
PPCB is trading near its 52-week low of $0.24 (10% above the low) on elevated volume (5.5× avg).
Summary
Propanc Biopharma, Inc. filed to register 2 million shares of common stock for resale by Hexstone Capital LLC, representing a significant portion of outstanding shares, with the company receiving no proceeds from this offering.
Key Events · Financing and Capital Events · PPCB
-
Selling Stockholder Resale
Hexstone Capital LLC is registering 2 million shares of common stock for resale, representing approximately 15% of the company's currently outstanding shares.
-
No Company Proceeds
Propanc Biopharma, Inc. will not receive any proceeds from the sale of these shares by the selling stockholder.
-
Highly Dilutive Financing Terms
The shares originate from Series C Preferred Stock and warrants convertible at a deep discount (85% of lowest trading price), indicating a highly dilutive financing structure.
-
Financial Distress Context
This resale occurs while the company faces a Nasdaq delisting notice (issued on 2026-01-07) and has expressed substantial doubt about its ability to continue as a going concern.
Analysis · PPCB · Life Sciences
This 424B3 filing registers 2 million shares of common stock for resale by Hexstone Capital LLC, an institutional investor. This represents approximately 15% of the company's currently outstanding shares and will create substantial selling pressure and dilution without providing any direct capital to Propanc Biopharma. The shares originate from a private placement of Series C Preferred Stock and warrants with highly dilutive conversion terms (85% of the lowest trading price). This event is particularly critical given the company's recent Nasdaq non-compliance notice for minimum bid price and its explicit disclosure of substantial doubt about its ability to continue as a going concern. The ongoing liquidation by a major investor, coupled with the company's dire financial state, signals significant challenges ahead for its stock price and operational viability.
How filings like this one have moved
In the 30 days to Sep 16, 2026, 35.8% of the 1190 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.45%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PPCB was trading at $0.27 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.7M. The 52-week trading range was $0.24 to $24.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.